研究者業績
基本情報
研究キーワード
5研究分野
1経歴
12-
2022年7月 - 現在
-
2022年7月
-
2015年4月 - 2022年6月
-
2013年7月 - 2022年6月
学歴
2-
2012年4月 - 2013年3月
-
1994年4月 - 2000年3月
委員歴
4-
2019年2月 - 現在
-
2018年4月 - 現在
-
2014年1月 - 2017年12月
受賞
8-
2019年2月
-
2012年10月
論文
100-
Infectious diseases and therapy 2025年4月10日 査読有りLower respiratory tract infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) and individuals of all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization and death. National administration schedules for available vaccines against respiratory viruses are not unified, and not all current guidelines are clear and directive, concerning the optimal timing of vaccination. Herein, we formulate an evidence-based position regarding the optimal timing of COVID-19, influenza, and RSV vaccination for older adults and individuals with chronic comorbidities, based on a synthesis of the literature and current guidelines. Vaccination impact and timing were found to be influenced by vaccinee risk factors, including age and comorbidities, and waning vaccine effectiveness and seasonal pathogen burden. Because COVID-19, influenza, and RSV display unique seasonal patterns within and between regions, local epidemiological surveillance of each virus is crucial for determining optimal vaccination timing and guidelines. To maximize the benefits of these respiratory virus vaccines, the timing of peak vaccine effectiveness and period of greatest risk for severe outcomes should be aligned. Thus, COVID-19, influenza, and other recommended vaccines given ahead of the start of the respiratory virus season (or other regionally appropriate time) and co-administered at a single, routine visit represent the optimal approach to protecting at-risk populations. More data will be required to establish the clinical benefit of additional RSV vaccine doses and whether these may be integrated within a seasonal schedule. Coordinated policy decisions that align with strain selection for new and annually reformulated vaccines would enable the timely raising of public health awareness, ultimately leading to enhanced vaccine uptake. Implementation strategies will require engagement of healthcare providers and strong, evidence-based public health recommendations for integrated vaccine schedules.
-
Infection Control & Hospital Epidemiology 2025年4月3日
-
Sexually Transmitted Diseases 2025年2月25日 査読有り最終著者責任著者
-
Infection Control & Hospital Epidemiology 2025年2月14日 査読有り最終著者責任著者
-
Asia-Pacific journal of public health 10105395241305929-10105395241305929 2024年12月17日 査読有りFew longitudinal studies have examined the impact of the COVID-19 pandemic on personal behaviors. This study investigated changes in four social behaviors among the Japanese public during and after the COVID-19 pandemic, using four-wave longitudinal data (2020-2023) from the Japan COVID-19 and Society Internet Survey (JACSIS). In total, 8622 respondents continuously participated in the surveys. In JACSIS 2023, the percentage of individuals who always refrained from specific actions decreased compared with 2020: traveling (71.0%-30.9%), non-essential and non-urgent outings (60.6%-24.5%), crowded spaces (62.6%-28.0%), and eating out (49.5%-21.6%). Mixed-effects logistic regression analysis indicated that essential health care workers displayed more cautious behavior than other workers, and respondents were less likely to refrain from these actions in JACSIS 2023 compared with 2020. Understanding behavioral changes is crucial to evaluating the efficacy of COVID-19 prevention measures and improving future pandemic response strategies.
MISC
106-
感染対策ICTジャーナル 6(4) 365-369 2011年10月
-
月刊薬事 53(5) 669-672 2011年5月
-
Intensivist 3(1) 25-32 2011年1月カテーテル関連血流感染症、とりわけ中心静脈カテーテル関連血流感染症central line associated bloodstream infection(CLABSI)は、集中治療室(ICU)において、最も重要な医療関連感染症の1つであり、ICUケアに与えるインパクトは患者予後あるいは医療経済の視点からみても大きい。ICUでのCLABSIの予防には、さまざまな対策が提案されているが、それらを組み合わせた、より包括的な予防策の施行が有効であることが明らかとなってきている。本稿では、CLABSIの背景、予防、そしてサーベイランスについて触れる。(著者抄録)
-
レジデントノ-ト 11 211-215 2009年10月
書籍等出版物
5共同研究・競争的資金等の研究課題
3-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2016年4月 - 2020年3月